NERV
NASD Minerva Neurosciences Inc$3.28 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.28, $0.09 below the day’s high of $3.37
- YTD change
- -18.41%
- vs 20-day SMA
- -13.15%
- vs 200-day SMA
- -35.17%
Price ranges
Price & Performance
-1.95 (-37.28%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.3% away from all-time highs of $121.72
- NERV is down 18% since the beginning of the year
- NERV is up 56% over the past 12 months
- NERV is down 27% over the past 1 month
- 5% of all NERV investors are betting against NERV
NERV reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +56.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- -4.93%
- vs 8-day SMA
- -4.51%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.